Literature DB >> 12764868

[Antimicrobial combination therapy].

Günter Weiss1.   

Abstract

Anti-microbial combination therapy is a very frequently used therapeutic approach although clinical data from prospective randomized trials thus fulfilling the criteria of evidence based medicine are very rare. Rationales for the use of combination therapy are thus empirical treatment of polymicrobial infections, infections in critical ill or in immuno-compromised patients, prevention of the emerge of antibiotic resistances, utilization of a potential synergism of antibiotics directed against a certain bacterial strain, or simply despair. Prospective studies have demonstrated a superiority of combination therapy over single drug regimen in enterococcal endocarditis, and infections with gram negative rods including pseudomonas sp., but in the latter condition only if the patient is severely immuno-compromised. There is clinical indication that combination therapy may be beneficial in infections with staphylococci sp., however, well designed studies supporting this experience are largely absent. Nonetheless, antimicrobial combination therapy also harbors some risks for patients which can be referred to potential antagonism between antibiotics, accumulation of side effects, or stimulation of resistance pathways in bacteria by one drug leading to destabilization of the other one. Thus, the insightful use of combination therapy is warranted and well designed, prospective studies are urgently needed to evaluate the true benefit of combination therapy for the treatment of different infections and specific micro-organisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764868     DOI: 10.1046/j.1563-258x.2003.03016.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  11 in total

Review 1.  Is monotherapy for febrile neutropenia still a viable alternative?

Authors:  R Ramphal
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

2.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.

Authors:  M Hilf; V L Yu; J Sharp; J J Zuravleff; J A Korvick; R R Muder
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

3.  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin.

Authors:  M H LEPPER; H F DOWLING
Journal:  AMA Arch Intern Med       Date:  1951-10

4.  Synergism and antagonism in double beta-lactam antibiotic combinations.

Authors:  L Gutmann; R Williamson; M D Kitzis; J F Acar
Journal:  Am J Med       Date:  1986-05-30       Impact factor: 4.965

5.  Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center.

Authors:  G L Mandell; D Kaye; M E Levison; E W Hook
Journal:  Arch Intern Med       Date:  1970-02

6.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

7.  Single-antibiotic therapy for streptococcal endocarditis.

Authors:  A W Karchmer; R C Moellering; D G Maki; M N Swartz
Journal:  JAMA       Date:  1979-04-27       Impact factor: 56.272

Review 8.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

Review 9.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

10.  Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.

Authors:  Y Siegman-Igra; R Ravona; H Primerman; M Giladi
Journal:  Int J Infect Dis       Date:  1998 Apr-Jun       Impact factor: 3.623

View more
  1 in total

1.  Outpatient prescription practices in rural township health centers in Sichuan Province, China.

Authors:  Qian Jiang; Bo Nancy Yu; Guiying Ying; Jiaqiang Liao; Huaping Gan; James Blanchard; Juying Zhang
Journal:  BMC Health Serv Res       Date:  2012-09-18       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.